News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BRAHMS AG, Cezanne and Lumiphore Inc. Announce Partnership for Diagnostic Tests



6/22/2009 9:40:11 AM

BERLIN, NIMES, France and RICHMOND, Calif., June 22 /PRNewswire/ -- BRAHMS Aktiengesellschaft, a global diagnostics company, Cezanne, and Lumiphore Inc., a biotechnology leader in new proprietary fluorescent metal-lanthanide technology for use in high-value applications, announced that they have signed an agreement on incorporation of Lumiphore's Lumi4(R)-Tb complexes in BRAHMS diagnostic tests.

Under the agreement, BRAHMS together with its subsidiary Cezanne, developer and manufacturer of KRYPTOR automated diagnostic solutions, has the non-exclusive rights to incorporate Lumi4(R) technology into current and future diagnostic tests and the exclusive rights to use the technology in diagnostic tests for Down's Syndrome including Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism.

"Lumiphore's goal is to bring the benefits of lanthanide-based homogenous assays to the diagnostic markets, from central labs to point-of-care applications. Detection sensitivity and simplicity of use as well as material cost reductions in reagent use, labor, and reader platforms are all benefits of Lumiphore's new reporter technology," said Steve Blose Lumiphore's Chief Business Officer.

"Using Lumi4(R)-Tb in the reader technology of our diagnostic tests will provide multiple benefits for BRAHMS. Thus we will take Lumi4(R)-Tb into consideration for the development of future analysis systems, both in laboratories and point-of-care-formats," said Ansgar Schmitt, BRAHMS' Vice President Business Development.

BRAHMS' KRYPTOR analysis systems can currently perform various analyses in random-access operations using TRACE (Time Resolved Amplified Cryptate Emission) technology, based on Forster resonance energy transfer (FRET). - FRET uses two fluorophores as a donor and an acceptor. The energy transfer between these two occurs when in nanometer scale proximity, which allows accurate measurement of molecular interactions. BRAHMS is using Nobel Prize winning cyrptand donor chemistry (J.M. Lehn, 1987) and will use Lumiphore's next generation terbium-donors in some of its future assays. "Using Lumi4(R)-Tb to replace the current Europium Cryptate will not only increase sensitivity of BRAHMS diagnostic tests, but will also allow the development of multiplexed assays - measuring 3-4 parameters in one test sample - be possible," explained Emmanuel Bois, Chief Executive Officer of Cezanne. In daily routine this would spare patients the burden of repeated blood withdrawal and in the same time save time and costs for the hospital.

Lumi4(R) complexes are a new class of fluorescent-metal lanthanide detection reagents based on technology patented by Professor Kenneth N. Raymond and coworkers at the University of California, Berkeley. Lanthanides are exceptional due to their long fluorescent lifetime delays that enable time gating and a dramatic drop in background noise when sensitized by the appropriate organic cage. This unique patent family is focused on a novel cage structure surrounding the terbium ion which enables them to be used as extremely efficient time resolved fluorescence (TRF) reporters, and fluorescent resonance energy transfer (FRET) donors in proximity binding assays. These complexes have long emission lifetimes and offer a number of major advantages over existing fluorophores used for detection, including very high signal-to-noise ratio, stability, elimination of photobleaching, and multiplexing.

This is the fourth strategic partnership reached by Lumiphore in the past three years. Previous partnerships include Cis Bio International (www.htrf.com/company/partners/) for the drug discovery research market; Echelon Biosciences Inc. (www.echelon-inc.com) for novel cancer assays involving phospholipid signaling; and Biophor Diagnostics Inc. for diagnostic tests for drugs of abuse.

About BRAHMS Aktiengesellschaft

The BRAHMS AG conducts researches, develops, produces and markets innovative diagnostic biomarkers. It is one of the three largest biotechnology companies in Germany. The company sells its products in more than 65 countries via its own subsidiary companies and sales organizations as well as laboratory systems from its own production and globally operating licensees. The headquarters of BRAHMS is at Hennigsdorf in Berlin, where about 220 employees out of 400 of the world wide employees of the company are posted.

About Lumiphore, Inc.

Based in Richmond, California, Lumiphore Inc, a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide technology for use in high-value applications which are commercialized through market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. For more information about Lumiphore, log onto www.lumiphore.com. Lumi4(R) is a registered mark of Lumiphore, Inc.

CONTACT: Stephen Blose, Chief Business Officer of Lumiphore, Inc.,
+1-415-318-4457, mvsgroup@msn.com; Emmanuel Bois, President, Cezanne, SAS,
+33 466 365 236, ebois@cezanne.fr; or Ingo Buchholzer, Public Relations
Manager, BRAHMS Aktiengesellschaft, + 49 3302 883-637,
i.buchholzer@brahms.de

Web site: http://www.lumiphore.com/
http://www.cezanne.fr/
http://www.brahms.de/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES